Jordi Mata-Fink, Gate Bioscience CEO

‘Small mol­e­cules are sexy again’: Gate Bio­science de­buts with $60M and a new way to stop dis­ease-caus­ing pro­teins

Gate Bio­science has raised $60 mil­lion to de­vel­op a new type of pill-based med­i­cine — which it calls a mol­e­c­u­lar gate — that can go af­ter the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.